Table 3.

Comparison of the outcomes reported in the non-stenting medical treatment-only groups of the SAMMPRIS and VISSIT trials with comparable outcomes in the OXVASC cohort

	Any stroke*or death <30 days and same territory ischaemic stroke >30 days†		Any stroke*or death†		Any stroke*†		Same territory ischaemic stroke or hard transient ischaemic attack (>2 days)‡		Same territory ischaemic stroke‡		Any territory hard transient ischaemic attack (>2 days)‡
	Events	Risk (95% CI)	Events	Cumulative risk (95% CI)	Events	Cumulative risk (95% CI)	Events	Cumulative risk (95% CI)	Events	Cumulative risk (95% CI)	Events	Cumulative risk (95% CI)
SAMMPRIS, n=227	34	14·1 % (10·1–19·4)	51	19·8% (15·1–25·6)	13	17·2% (12·9–22·9)	..	..	..	..	..	..
VISSIT, n=53	..	..	..	..	..	..	8	15·1% (6·7–27·6)	5	9·4% (3·1–20·7)	3	5·7% (1·2–15·7)
All OXVASC 50–99% symptomatic intracranial stenosis, n=94	8	9·0% (2·9–15·1)	21	23·4% (14·6–32·2)	9	10·8% (3·9–17·7)	11	12·0% (5·3–18·7)	5	5·5% (0·8–10·2)	7	7·6% (2·1–13·1)
OXVASC 50–99% symptomatic intracranial stenosis excluding atrial fibrillation, n=74	6	8·2% (1·9–14·5)	16	22·6% (12·8–32·4)	6	8·9% (2·0–15·8)	8	11·1% (3·9–18·4)	4	5·6% (0·3–11·1)	5	6·9% (1·0–12·8)
OXVASC 70–99% symptomatic intracranial stenosis fulfilling trial criteria, n=36	2	5·6% (0·0–13·0)	8	22·7% (8·8–36·6)	3	9·2% (0·0–19·2)	5	13·9% (2·5–25·3)	2	5·6% (0·0–13·0)	3	8·3% (0·0–17·3)

^*Any stroke includes ischaemic stroke, intracerebral haemorrhage, or subarachnoid haemorrhage.

^†SAMMPRIS 2-year outcome.

^‡VISSIT 1-year outcome.